Sulforaphanoids - new potential antidiabetic compounds
| Reference number | |
| Coordinator | Lunds universitet - Institutionen för kliniska vetenskaper, Kansliet, Malmö |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | December 2014 - August 2015 |
| Status | Completed |
Purpose and goal
The goals of the programme will be to validate sulforaphanoids for the treatment of liver insulin resistance in T2D to progress the project towards preclinical proof of concept. We have identified one sulforaphanoid that is stable with high membrane permeability. We will now proceed with in vivio effect studies using this compound.
Results and expected effects
The sulforaphanoid that we have chosen to proceed with is hydrolyzed to sulforaphane at latest in the liver. We have also characterized its pharmacokinetic properties and also found that the compound has a bioavailability of 78% after oral administration in mice. We will now proceed with in vivo efficacy studies with ZE438 as a further step towards potential clinical phase I studies. PULS will be our partner of choice for further commecialisation after clinical proof-of-concept studies, if successful.
Approach and implementation
We have adhered to our planned scheme for identification and analysis of different sulforaphanoids. Next steps will be to proceed with effect studies using the most promising sulforaphanoid.